Today

Agents

Chat

Arena

Discover

More

App

VivoSim forecasts FY2027 revenue growth of 500%+

VIVS•2026-07-15

FY2027 revenue outlook and Lilly milestone

VivoSim forecast FY2027 revenue growth of more than 500%, citing rising demand for its NAM-based contract research services from drugmakers.

Guidance followed receipt of a $5 million Eli Lilly milestone tied to first patient dosing in a Phase 2 study of a former VivoSim IBD drug.

The company is eligible for up to $45 million in additional Lilly milestones if the program meets future regulatory and commercial targets.

Related News

US Stocks-Wall St set to open higher as investors weigh earnings; PayPal jumps

SPY•2026-07-15

NeOnc Technologies notifies availability of announcement on FDA feedback for NEO212 development

NTHI•2026-07-15

Quality Industrial sets USD 1.68 million installment repayment plan with RB Capital Partners for past-due notes

QIND•2026-07-15

Comcast Corp <CMCSA.O>: JP Morgan Cuts Target Price to $29 From $33

CMCSA•2026-07-15

Cintas Q4 revenue beats estimates

CTAS•2026-07-15

VivoSim forecasts FY2027 revenue growth of 500%+ - VIVS News | Rallies